S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Macron booed by French farmers who blame him for not doing enough to support agriculture
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Macron booed by French farmers who blame him for not doing enough to support agriculture
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Macron booed by French farmers who blame him for not doing enough to support agriculture
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Macron booed by French farmers who blame him for not doing enough to support agriculture
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
NASDAQ:TMCI

Treace Medical Concepts (TMCI) Stock Price, News & Analysis

$14.25
-0.14 (-0.97%)
(As of 02/23/2024 ET)
Today's Range
$14.12
$14.74
50-Day Range
$10.22
$15.86
52-Week Range
$5.27
$27.97
Volume
477,832 shs
Average Volume
394,663 shs
Market Capitalization
$878.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.58

Treace Medical Concepts MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
37.4% Upside
$19.58 Price Target
Short Interest
Bearish
6.62% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.07mentions of Treace Medical Concepts in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.79) to ($0.50) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.56 out of 5 stars

Medical Sector

428th out of 939 stocks

Surgical & Medical Instruments Industry

53rd out of 93 stocks


TMCI stock logo

About Treace Medical Concepts Stock (NASDAQ:TMCI)

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision; and Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

TMCI Stock Price History

TMCI Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
TMCI Sep 2024 20.000 call
TMCI Jun 2024 22.500 call
TMCI Mar 2024 17.500 call
TMCI Mar 2024 25.000 call
AI medical stock landing MASSIVE contracts
The company is tiny today, but big pharma is lining up to use its patent-protected technology. In short, it is the inventor of the world's first AI-designed drug to enter clinical trials. Currently, the stock trades for less than $10 today and is at the forefront of it all.
Treace Medical Concepts Inc (TMCI)
BTIG Reaffirms Their Buy Rating on Treace Medical Concepts (TMCI)
6 Analysts Assess Treace Medical Concepts: What You Need To Know
Treace Medical Concepts Inc TMCI
See More Headlines
Receive TMCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Treace Medical Concepts and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/08/2023
Today
2/25/2024
Next Earnings (Confirmed)
2/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:TMCI
Fax
N/A
Employees
423
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$19.58
High Stock Price Target
$27.50
Low Stock Price Target
$11.00
Potential Upside/Downside
+37.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-42,810,000.00
Pretax Margin
-27.28%

Debt

Sales & Book Value

Annual Sales
$174.68 million
Book Value
$1.09 per share

Miscellaneous

Free Float
43,981,000
Market Cap
$878.88 million
Optionable
Optionable
Beta
0.28
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. John T. TreaceMr. John T. Treace (Age 52)
    CEO, Founder & Director
    Comp: $1.04M
  • Mr. Mark L. Hair CPA (Age 54)
    Chief Financial Officer
    Comp: $628.6k
  • Mr. Aaron J. Berutti (Age 45)
    Senior Vice President of Sales
    Comp: $519.41k
  • Mr. Terry W. Lubben (Age 59)
    Senior Vice President of Operations
  • Ms. Julie D. Dewey (Age 63)
    Chief Communications & Investor Relations Officer
  • Mr. Scot M. Elder (Age 49)
    Chief Legal & Compliance Officer and Corporate Secretary
  • Mr. Nathan Minnich
    Senior Vice President of Marketing
  • Mr. Daniel E. Owens (Age 52)
    Chief Human Resources Officer
  • Dr. Sean F. Scanlan Ph.D. (Age 41)
    Chief Innovation Officer
  • Ms. Shana Zink
    Senior Vice President of Clinical Affairs, Medical Education & Reimbursement














TMCI Stock Analysis - Frequently Asked Questions

Should I buy or sell Treace Medical Concepts stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Treace Medical Concepts in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TMCI shares.
View TMCI analyst ratings
or view top-rated stocks.

What is Treace Medical Concepts' stock price target for 2024?

6 brokerages have issued 12-month price objectives for Treace Medical Concepts' stock. Their TMCI share price targets range from $11.00 to $27.50. On average, they expect the company's stock price to reach $19.58 in the next year. This suggests a possible upside of 37.4% from the stock's current price.
View analysts price targets for TMCI
or view top-rated stocks among Wall Street analysts.

How have TMCI shares performed in 2024?

Treace Medical Concepts' stock was trading at $12.75 on January 1st, 2024. Since then, TMCI shares have increased by 11.8% and is now trading at $14.25.
View the best growth stocks for 2024 here
.

Are investors shorting Treace Medical Concepts?

Treace Medical Concepts saw a increase in short interest during the month of January. As of January 31st, there was short interest totaling 2,850,000 shares, an increase of 10.9% from the January 15th total of 2,570,000 shares. Based on an average trading volume of 964,800 shares, the days-to-cover ratio is currently 3.0 days. Approximately 6.6% of the company's shares are short sold.
View Treace Medical Concepts' Short Interest
.

When is Treace Medical Concepts' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our TMCI earnings forecast
.

How can I listen to Treace Medical Concepts' earnings call?

Treace Medical Concepts will be holding an earnings conference call on Tuesday, February 27th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Treace Medical Concepts' earnings last quarter?

Treace Medical Concepts, Inc. (NASDAQ:TMCI) issued its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.20) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.03. The firm had revenue of $41.95 million for the quarter, compared to analyst estimates of $40.84 million. Treace Medical Concepts had a negative trailing twelve-month return on equity of 37.68% and a negative net margin of 27.28%. The firm's revenue was up 40.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.23) earnings per share.

What guidance has Treace Medical Concepts issued on next quarter's earnings?

Treace Medical Concepts updated its FY 2023 earnings guidance on Tuesday, January, 30th. The company provided EPS guidance of for the period. The company issued revenue guidance of $186.7 million-$187.1 million, compared to the consensus revenue estimate of $183.9 million.

When did Treace Medical Concepts IPO?

(TMCI) raised $150 million in an IPO on Friday, April 23rd 2021. The company issued 9,400,000 shares at $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and SVB Leerink and Stifel were co-managers.

Who are Treace Medical Concepts' major shareholders?

Treace Medical Concepts' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (6.96%), Armistice Capital LLC (4.63%), TimesSquare Capital Management LLC (2.84%), CIBC Private Wealth Group LLC (2.37%), Norges Bank (1.11%) and Northern Trust Corp (0.65%). Insiders that own company stock include Aaron Berutti, Daniel E Owens, F Barry Bays, Jaime A Frias, James T Treace, John R Treace, John T Treace, Mark Hair, Richard W Mott, Scot Michael Elder, Sean F Scanlan, Terry W Lubben and Thomas E Timbie.
View institutional ownership trends
.

How do I buy shares of Treace Medical Concepts?

Shares of TMCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TMCI) was last updated on 2/25/2024 by MarketBeat.com Staff